Liquidia Co. (NASDAQ:LQDA – Get Free Report) General Counsel Russell Schundler sold 1,985 shares of the stock in a transaction on Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $24,872.05. Following the sale, the general counsel now owns 485,676 shares in the company, valued at approximately $6,085,520.28. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Russell Schundler also recently made the following trade(s):
- On Monday, June 3rd, Russell Schundler sold 710 shares of Liquidia stock. The shares were sold at an average price of $14.55, for a total value of $10,330.50.
Liquidia Price Performance
Shares of NASDAQ:LQDA traded down $0.17 on Monday, hitting $12.44. 679,382 shares of the company’s stock were exchanged, compared to its average volume of 866,789. The business’s 50 day simple moving average is $12.73 and its two-hundred day simple moving average is $13.45. The stock has a market capitalization of $950.54 million, a price-to-earnings ratio of -7.97 and a beta of 0.32. Liquidia Co. has a 12 month low of $5.71 and a 12 month high of $16.99.
Institutional Trading of Liquidia
Several institutional investors and hedge funds have recently made changes to their positions in LQDA. Vanguard Group Inc. boosted its position in Liquidia by 1.0% during the third quarter. Vanguard Group Inc. now owns 2,774,398 shares of the company’s stock valued at $17,590,000 after purchasing an additional 26,678 shares in the last quarter. Fortitude Family Office LLC bought a new stake in Liquidia during the fourth quarter valued at about $26,000. SG Americas Securities LLC boosted its position in Liquidia by 17.4% during the fourth quarter. SG Americas Securities LLC now owns 15,540 shares of the company’s stock valued at $187,000 after purchasing an additional 2,298 shares in the last quarter. Bleakley Financial Group LLC boosted its position in Liquidia by 45.6% during the fourth quarter. Bleakley Financial Group LLC now owns 31,193 shares of the company’s stock valued at $375,000 after purchasing an additional 9,764 shares in the last quarter. Finally, LB Partners LLC bought a new stake in Liquidia during the fourth quarter valued at about $3,404,000. 64.54% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of Liquidia in a research note on Wednesday, July 10th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 target price on shares of Liquidia in a research report on Monday, June 3rd. Finally, Oppenheimer assumed coverage on Liquidia in a research report on Tuesday, June 25th. They set a “market perform” rating for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $21.60.
Read Our Latest Report on LQDA
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
See Also
- Five stocks we like better than Liquidia
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- Where to Find Earnings Call Transcripts
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- Why is the Ex-Dividend Date Significant to Investors?
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.